Chikungunya infections in the Caribbean region Since August 2014, there has been an increase in the number of Chikungunya patients in the Caribbean region. Travellers who visit the region can become infected there.
Dr. Els van Schie new director of Environment and Safety Dr. Els van Schie has been appointed RIVM Director of Environment and Safety as from 1 February 2015. She will succeed Dr. Marcel van Raaij and interim director Dr.
Release of QMRAspot v2 for quantitative microbial risk assessment of drinking water RIVM has developed a new version of QMRAspot (2.0), a user-friendly computational tool to calculate the risk of becoming infected by pathogenic microorganisms in drinking water.
Annoyance and health effects due to European transportation noise At least 20 million adults in Europe are annoyed by transportation noise in agglomerations, from motorways, airports or railways.
Statistical Program to Assess Dietary Exposure now available The Statistical Program to Assess Dietary Exposure (SPADE), developed by RIVM, is now available.
Citizen science network produces accurate maps of fine air particles Measurements by thousands of citizen scientists in the Netherlands using their smartphones and the iSPEX add-on are delivering accurate data on fine air particles in the atmosphere that add valuabl
Sustainability of EU regulatory system on medicinal products In safeguarding the quality, safety and efficacy of medicinal products, the present EU regulatory system has become a time consuming and highly regulated process.
Mental care still the most expensive of all In 2011, 19.6 billion euros was spent on the treatment of mental disorders. This amounted to 22% of the total expenditure on health and welfare during that year.
Risks of eHealth technology RIVM and Nictiz have made an overview of the risks that eHealth applications may entail and how these risks can be controlled.
Key organisations unite to improve benefit and risk assessments of vaccines Leading organisations have joined forces to launch a unique project that will pave the way for a pan-European framework for rapidly assessing and communicating the benefits and risks of vaccines.